AbbVie (ABBV)
$173.22
0.39 (0.22%)
ABBV Stock Quote Delayed 30 Minutes
The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase
There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.62M
Day's Range
$172.84 - $174.59
52-Week Range
$135.85 - $182.89
Dividend & Yield
$5.92 (3.42%)
ABBV Stock Predictions, Articles, and AbbVie News
AbbVie Is Cheap and Pays an Attractive Yield
AbbVie stock is both cheap and has an attractive dividend yield. AbbVie stock sells below 10x earnings, with a 4.9% dividend yield and a 28% upside target value.
Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk
Analysts call ABBV stock a bargain after its $63 billion purchase of Allergan, whose existing drugs and pipeline are now expected to replace revenue from Humira.
AbbVie Will Be in Big Trouble When Its Patent Cliff Arrives
ABBV stock may seem like an attractive value name. But while it is very profitable now, things are set to worsen dramatically in a few years..
AbbVie Stock Is More Than a Great Dividend Payer
It's fine if you want to hold ABBV stock for the dividend payouts, but there are also other reasons to own it.
AbbVie Stock Is a Winner in the Pharmaceutical Industry
The public health crisis threw AbbVie into the spotlight but the company handled the ongoing crisis better than its competitors. With a successful acquisition and a high dividend yield. ABBV stock is a safe bet for investors in a volatile market.
AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions
With AbbVie's buyout of Allergan officially finalized, ABBV stock has moved significantly higher since then. However, ABBV is so much more than this headline event.
It’s Time to Buy AbbVie Stock Now After Its Allergan Purchase
AbbVie stock needed its merger with AGN stock to diversify. Now that it has, the stock has more potential upside thanks to Allergan.
Stock Market Today: Disney Halts Dividend; Worst ADP Report Ever
Disney missed on earnings but reported strong growth in streaming. Nio's deliveries doubled. Here's what happened in the stock market today.
5 Top Stock Trades for Wednesday: ATVI, SHOP, CHGG, ABT, ABBV
Activision Blizzard, Shopify, Chegg, Abbott Labs and AbbVie were our top stock trades for Wednesday. That said, here's a look at the charts.
AbbVie Earnings: 5 Things for ABBV Stock Investors to Know About Q1
AbbVie (ABBV) earnings for the biopharmaceutical company's first quarter of 2020 have ABBV stock on the move Friday after beating estimates.
The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors
The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.
Why You Can Buy AbbVie At a Massive Discount
ABBV stock does not fully reflect the deep pipeline of drugs under development and the billions in future sales from two key drugs.
Buy AbbVie Stock as the Drugmaker Diversifies Its Pipeline
With a major acquisition in the works, ABBV stock isn't just a dividend king, but a rapidly-diversifying juggernaut.
Ignore the Coronavirus Catalyst for ABBV Stock
Without a coronavirus treatment, the medical community is experimenting with repurposed drugs. In this regard, the present crisis may benefit ABBV stock. Still, AbbVie has other headwinds that investors shouldn’t ignore.
